Literature DB >> 17052490

Benzoyl peroxide/clindamycin/UVA is more effective than fluticasone/UVA in progressive macular hypomelanosis: a randomized study.

Germaine N Relyveld1, Melanie M Kingswijk, Johannes B Reitsma, Henk E Menke, Jan D Bos, Wiete Westerhof.   

Abstract

BACKGROUND: There is no effective treatment for progressive macular hypomelanosis. Recent findings indicate that Propionibacterium acnes may play a role in the pathogenesis.
OBJECTIVES: We sought to compare the effectiveness of antimicrobial therapy with anti-inflammatory therapy in patients with progressive macular hypomelanosis.
METHODS: A total of 45 patients were randomized to a within-patient left-right comparison study of benzoyl peroxide 5% hydrogel/clindamycin 1% lotion in combination with UVA irradiation versus fluticasone 0.05% cream in combination with UVA irradiation. Repigmentation was determined by photometric measurements of changes in skin color and by patient and dermatologist assessment using before and after photographs.
RESULTS: Benzoyl peroxide 5% hydrogel, clindamycin 1% lotion, and UVA led to better repigmentation than fluticasone 0.05% cream in combination with UVA irradiation in all measurements. (Photometric measurements P = .007, patient assessment P < .0001, and dermatologist assessment P < .0001.) LIMITATIONS: There was difficult objective color measurement. Therefore, subjective assessment has important additional value. Right-left comparisons have certain inherent limitations.
CONCLUSION: Antimicrobial therapy in conjunction with light was more effective in repigmentation in patients with progressive macular hypomelanosis than a combination of anti-inflammatory therapy and light.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17052490     DOI: 10.1016/j.jaad.2006.03.020

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

1.  Progressive macular hypomelanosis in korean patients: a clinicopathologic study.

Authors:  Seon Wook Hwang; Soon Kwon Hong; Sang Hyun Kim; Jeong Hoon Park; Jong Keun Seo; Ho Suk Sung; Deborah Lee
Journal:  Ann Dermatol       Date:  2009-08-31       Impact factor: 1.444

2.  Progressive macular hypomelanosis: a rarely diagnosed hypopigmentation in Caucasians.

Authors:  Sven Neynaber; Christina Kirschner; Stefanie Kamann; Gerd Plewig; Michael J Flaig
Journal:  Dermatol Res Pract       Date:  2009-06-01

3.  Progressive macular hypomelanosis among Egyptian patients: a clinicopathological study.

Authors:  Mohamed Khaled Selim; El-Shahat Farag Ahmed; Mamdouh Morsy Abdelgawad; Mohammed Fawzy El-Kamel
Journal:  Dermatol Pract Concept       Date:  2011-01-31

4.  Strains of the Propionibacterium acnes type III lineage are associated with the skin condition progressive macular hypomelanosis.

Authors:  Emma Barnard; Jared Liu; Eliza Yankova; Silvana M Cavalcanti; Marcelo Magalhães; Huiying Li; Sheila Patrick; Andrew McDowell
Journal:  Sci Rep       Date:  2016-08-24       Impact factor: 4.379

5.  Propionibacterium Acnes Phylogenetic Type III is Associated with Progressive Macular Hypomelanosis.

Authors:  Rolf L W Petersen; Christian F P Scholz; Anders Jensen; Holger Brüggemann; Hans B Lomholt
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2017-02-27

6.  A quantitative analysis of Propionibacterium acnes in lesional and non-lesional skin of patients with progressive macular hypomelanosis by real-time polymerase chain reaction.

Authors:  Silvana Maria de Morais Cavalcanti; Emmanuel Rodrigues de França; Marcelo Magalhães; Ana Kelly Lins; Laura Costa Brandão; Vera Magalhães
Journal:  Braz J Microbiol       Date:  2011-06-01       Impact factor: 2.476

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.